LEI 5493003B21V1L9F31J13

NOVARTIS PHARMA AG

Group parent: NOVARTIS AGNOVN · SW

Awards tracked

76

Value

€567,954

Countries

CH

Download sample CSV

Contract awards & public grants

Advancing Novel Approaches in Kinase Interface Networks → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2026-06-17

—

FORTIFY - FRAMEWORK FOR OPTIMIZED REGULATION, TRADE SECRETS, AND INTELLECTUAL PROPERTY IN A FEDERATED EUROPEAN HEALTH DATA SPACE → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2026-06-02

—

SINGLE DOSE CURE OF FALCIPARUM MALARIA USING NEXT GENERATION COMBINATIONS → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2026-05-22

€37,500

Quantifying Atrial Fibrillation Burden to inform Screening, Treatment, and hEalth Policy → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2025-12-17

—

Cities@Heart: City-based Strategies for improving Cardiovascular Health in Europe → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2025-12-17

—

Patient Relevant Osteoarthritis endpoints using Big data Evaluation → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2025-12-02

—

Breakthrough Regulatory Innovation and Development throuGh sandbox Environments → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2025-11-07

—

Unifying Framework for Patient-centred Clinical-study Endpoints derived from Digital Health Technologies → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2025-11-03

—

Patient-Centric blOod saMpling FOr impRoved healThcare (Project-COMFORT) → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2024-12-16

—

Comprehensive methodological and operational approach to clinical trials in rare and ultra-rare diseases → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2024-12-12

—

IMAGING FOR PATIENT BENEFIT IN ARTHRITIS → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2024-12-10

—

REpresentative Clinical Research - ADvancing Inclusivity in Europe → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2024-12-05

—

Reducing Non-Human Primates in Non-Clinical Safety Assessment: The European Initiative on Minipig and Micropig Models → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2024-11-12

—

Developing and implementing VIrtual Control groups To reducE animal use in toxicology Research → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2024-07-26

—

Late-stage photocatalytic functionalization of alkenes and 1,3-dienes → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2024-03-13

—

Asymmetric carbyne catalytic transfer to streamline synthesis of chiral β-amino carbonyls → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2024-03-01

—

Innovative designs, extrapolation, simulation methods and evidence-tools for rare diseases addressing regulatory needs → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2023-11-16

—

Metal-containing Radical Enzymes → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2022-07-06

—

Innovative Mechanochemical Processes to synthesize green ACTIVE pharmaceutical ingredients. → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2022-05-23

—

European platform for neurodegenerative disorders → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2021-10-25

—

Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technologies → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2021-10-13

—

Health Initiatives in Psoriasis and PsOriatic arthritis ConsoRTium European States → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2021-06-29

—

Central Repository for Digital Pathology → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2020-11-26

—

Gravitate–Health: Empowering and Equipping Europeans with health information for Active Personal Health Management and Adherence to Treatment → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2020-11-12

—

Accelerating Research & Development for Advanced Therapies → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2020-11-11

—

H2O Health Outcomes Observatory → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2020-09-30

—

Corona Accelerated R&D in Europe → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2020-08-07

—

Prioritisation and Risk Evaluation of Medicines in the EnviRonment → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2020-06-24

—

C-H Activation for Industrial Renewal → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2020-06-22

—

HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY – PLUS → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2020-05-26

—

Translational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2020-04-16

—

Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2019-12-17

—

PharmaLedger → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2019-12-16

—

EU Patient- cEntric clinicAl tRial pLatform → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2019-11-27

—

Immune Safety Avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2019-11-18

—

Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2019-09-26

—

Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2019-08-22

—

Trials@Home: Center of Excellence – Remote Decentralised Clinical Trials → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2019-08-07

—

MachinE Learning Ledger Orchestration for Drug DiscoverY → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2019-05-22

—

Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed w → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2019-05-06

—

Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diag → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2019-04-08

—

Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2019-03-22

—

Neurotoxicity De-Risking in Preclinical Drug Discovery → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2019-03-15

—

Biomarkers in Atopic Dermatitis and Psoriasis → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2019-02-27

—

FAIRplus → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2018-12-18

—

NEw Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2018-12-18

—

Investigating Mechanisms and Models Predictive of Accessibility of Therapeutics (IM2PACT) Into The Brain → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2018-12-14

—

Remote Assessment of Disease and Relapse – Alzheimer’s Disease → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2018-12-05

—

European Health Data and Evidence Network → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2018-11-22

—

WEB-RADR 2 → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2018-09-10

—

Peroxisome Interactions and Communication → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2018-08-30

—

Research empowerment on solute carriers (ReSOLUTE) → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2018-06-22

—

Autism Innovative Medicine Studies – 2 – Trials → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2018-06-22

—

conect4children (COllaborative Network for European Clinical Trials For Children) → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2018-06-22

—

Ensuring the future of EUPATI beyond 2020 → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2018-06-21

—

Patients Active in Research and Dialogues for an Improved Generation of Medicines: Advancing meaningful patient engagement in the life cycle of medici → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2018-06-04

—

Improving the care of patients suffering from acute or chronic pain → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2018-05-04

—

Liver Investigation: Testing Marker Utility in Steatohepatitis → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2017-10-09

—

Enhacing TRANslational SAFEty Assessment through Integrative Knowledge Management → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2017-09-12

—

Develop and validate appropriate and acceptable outcome measures in intermediate age-related macular degeneration for future interventional clinical t → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2017-09-12

—

European Quality In Preclinical Data → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2017-08-18

—

Big Data 4 Better Hearts - Sofia ref.: 116074 → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2017-06-26

—

Inhibiting Misfolded protein PRopagation in Neurodegenerative Diseases - Sofia ref.: 116060 → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2017-04-07

—

CRG International Research Postdoctoral Programme → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2017-03-23

—

Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation - Sofia ref.: 116055 → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2017-01-30

—

Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY - Sofia ref.: 116026 → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2016-12-22

—

Real world Outcomes across the AD spectrum for better care: Multimodal data Access Platform - Sofia ref.: 116020 → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2016-12-21

—

Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966 → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2016-10-21

—

Psychiatric Ratings using Intermediate Stratified Markers - Sofia ref.: 115916 → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2015-12-18

—

Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes – → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2015-12-07

—

Accelerated Development of Appropriate Patient Therapies: a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes - Sofia ref.: → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2015-09-02

—

Accelerated Early staGe drug diScovery → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2015-08-11

€265,227

FRAGments training NETwork → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2015-08-11

€265,227

Connected Health Early Stage Researcher Support System → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2015-07-29

—

Calcium-Sensing Receptor (CaSR): Therapeutics for Non-Communicable Diseases → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2015-07-17

—

Design and development of advanced NAnomedicines to overcome Biological BArriers and to treat severe diseases → NOVARTIS PHARMA AG

European Commission · CH · Grant · 2014-12-05

—

Entity identity is matched from published recipient names and registry IDs to GLEIF legal-entity records; matches can be imperfect. Source records are public procurement and grant notices.